Thursday, September 18, 2014 7:34:46 AM
Milestone Scientific Receives CE Mark Approval for Epidural Injection System
LIVINGSTON, NJ--(Marketwired - September 18, 2014) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that its subsidiary, Milestone Medical, has received CE Mark to market and sell its epidural injection system in Europe. The CompuFlo™ Epidural Computer Controlled Anesthesia System (CompuFlo™ Epidural Model 6000) is intended for the verification of needle tip placement in the lumbar epidural space in patients over age of 18 and the delivery of medication and other fluids in a controlled manner in the lumbar epidural space as part of an in-patient or out-patient procedure established by their Health Care Provider.
Leonard Osser, Chief Executive Officer of Milestone Scientific, stated, "CE approval for our subsidiary's epidural instrument follows the recent CE approval of its intra-articular instrument. CE approval is an important achievement and further validation of our technology as our subsidiary moves towards commercial sale of the epidural injection system. Our subsidiary's next steps involve securing strategic partners to distribute its products in Europe, as it has already done in the U.S. Injection technology has not changed meaningfully since the advent of the hypodermic syringe over 150 years ago. Millions of patients that require epidural drug delivery and millions of women who give birth each year choose not to have an epidural due primarily to safety concerns about the high risks associated with this injection. Epidurals represent a multi-billion dollar global market and we believe our technology can transform these injections from an art to a science."
Milestone's injection technology is based on a patented Dynamic Pressure Sensing® system (DPS®), intended to measure the density of body tissue and thus help a clinician know the location of a hypodermic needle during an injection. The system utilizes computer controlled technology to provide real-time feedback to the medical practitioner and identify with precision when a needle has reached the location where a drug should be administered to a patient. It has the added advantage in other application of controlling the pain that patients typically associate with injections.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Recent MLSS News
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida • GlobeNewswire Inc. • 04/03/2024 12:30:00 PM
- Milestone Scientific Achieves 12% Increase in Revenue and 39% Increase in Gross Profit for the Year Ended 2023 • GlobeNewswire Inc. • 04/01/2024 11:00:00 AM
- Milestone Scientific Schedules 2023 Year-End Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 03/28/2024 03:45:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Omaha Pain Physicians • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® with Meridian Endo & Perio • GlobeNewswire Inc. • 02/28/2024 01:30:00 PM
- Milestone Scientific Commences Direct Sales of STA Single Tooth Anesthesia System® to Maine Dental Group, a Premier Group Practice with 21 Locations Across the Northeast • GlobeNewswire Inc. • 02/20/2024 01:30:00 PM
- Milestone Scientific CEO Provides Letter to Shareholders; Provides Positive Reimbursement Update • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 09:34:33 PM
- Milestone Scientific Inc. Announces Closing of $3.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/13/2023 10:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 05:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 10:21:29 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/12/2023 10:10:53 PM
- Milestone Scientific Inc. Announces Pricing of $3.0 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/11/2023 01:33:45 AM
- Milestone Scientific Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 12/08/2023 09:03:25 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/08/2023 09:00:28 PM
- Milestone Scientific Commences Sales of CompuFlo® Disposables for Use in Neurostimulation Spinal Cord Implantation Procedures • GlobeNewswire Inc. • 12/08/2023 01:30:00 PM
- Milestone Announces Agreement with Bioline Supply to Distribute the CompuFlo® Epidural System and Related Disposables Across Spain • GlobeNewswire Inc. • 11/28/2023 01:30:00 PM
- Milestone Scientific Achieves Revenue of $2.1 Million and Provides Business Update for the Third Quarter of 2023 • GlobeNewswire Inc. • 11/15/2023 12:00:00 PM
- Milestone Scientific Schedules Third Quarter 2023 Financial Results and Business Update Conference Call • GlobeNewswire Inc. • 11/10/2023 01:30:00 PM
- Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York • GlobeNewswire Inc. • 11/09/2023 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/31/2023 04:15:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/23/2023 09:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 09:39:33 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/19/2023 06:36:15 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 10/17/2023 08:03:04 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM